Lennard Lee, DPhil (Oxon), MRCP-UK, BmBCh (Oxon), MA (Cantab), leads clinical research into COVID-19 and cancer at the University of Birmingham, UK. He trained in medicine at the Universities of Cambridge and Oxford, where he undertook research in the Department of Physiology looking at viral gene therapy. He has worked at Guy's and St Thomas' Hospital, Royal Marsden Hospital and King's College London. He was then awarded a prestigious DPhil as a MRC Clinical Training Research Fellowship at the Wellcome Trust Centre for Human Genetics at the University of Oxford looking at "genetic determinants of colorectal cancer metastasis". He has also worked at the Oxford BRC centre prior to his recruitment to the Institute of Cancer and Genomic Sciences at the University of Birmingham in 2017. He is the co-lead on the UK Coronavirus Cancer Monitoring Project, a UK-led initiative for collaborative emergency research into the effects of COVID-19 in cancer patients.
Browse specialties
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs
ctDNA and bladder cancer: Current understanding and beyond
ROS1 fusion-positive NSCLC
NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC
Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy
ALK fusion-positive NSCLC: International approaches to management
RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC
COVID-19 & cancer
Conferences